A survey among breast cancer specialists on the low uptake of therapeutic prevention with tamoxifen or raloxifene

Silvia Noonan, Ambra Pasa, Vincenzo Fontana, Silvia Caviglia, Bernardo Bonanni, Alberto Costa, Samuel G Smith, Fedro Peccatori, Andrea DeCensi

Research output: Contribution to journalArticle

Abstract

With this survey, we aimed to address the reasons why physicians are reluctant to prescribe breast cancer preventive therapy with the selective oestrogens receptor modulators (SERMs) tamoxifen or raloxifene despite a strong evidence of efficacy. A self-administered 5-point Likert questionnaire was given during breast cancer meetings in Europe or sent via email to rank the importance of 10 pre-defined reasons for low uptake of SERMs for breast cancer therapeutic prevention. Analyses tested the associations between the stated reasons and physician characteristics such as gender, age, country of work and specialty. Of 246 delivered questionnaires, 27 were incomplete and were excluded from analysis. Overall, there was a small variability in response scores, with a tendency for physicians to give moderate importance (score=3) to all 10 statements. However, the top five reasons were: the expected greater preventive effectiveness of aromatase inhibitors (70.3% with score>3), difficulty applying current risk models in clinical practice (69.9%), the lack of clarity on the most appropriate physician for prevention advice (68.4%), the lack of reliable short-term biomarkers of effectiveness (67.5%) and the lack of commercial interest in therapeutic prevention (66.0%). The lack of reliable short-term biomarkers showed a tendency to discriminate between medical oncologists and other breast specialists (OR=2.42, 95% CI, 0.93-6.25). This survey highlights the complexity of prescribing decisions among physicians in this context. Coupled with the known barriers among eligible women, these data may help to identify strategies to increase uptake of breast cancer therapeutic prevention.

Original languageEnglish
JournalCancer Prevention Research
DOIs
Publication statusE-pub ahead of print - Oct 23 2017

Fingerprint

Tamoxifen
Breast Neoplasms
Physicians
Selective Estrogen Receptor Modulators
Biomarkers
Therapeutics
Aromatase Inhibitors
Breast
Raloxifene Hydrochloride
Surveys and Questionnaires

Keywords

  • Journal Article

Cite this

A survey among breast cancer specialists on the low uptake of therapeutic prevention with tamoxifen or raloxifene. / Noonan, Silvia; Pasa, Ambra; Fontana, Vincenzo; Caviglia, Silvia; Bonanni, Bernardo; Costa, Alberto; Smith, Samuel G; Peccatori, Fedro; DeCensi, Andrea.

In: Cancer Prevention Research, 23.10.2017.

Research output: Contribution to journalArticle

@article{665a0bae7c694d95b144ce3b2a14f25a,
title = "A survey among breast cancer specialists on the low uptake of therapeutic prevention with tamoxifen or raloxifene",
abstract = "With this survey, we aimed to address the reasons why physicians are reluctant to prescribe breast cancer preventive therapy with the selective oestrogens receptor modulators (SERMs) tamoxifen or raloxifene despite a strong evidence of efficacy. A self-administered 5-point Likert questionnaire was given during breast cancer meetings in Europe or sent via email to rank the importance of 10 pre-defined reasons for low uptake of SERMs for breast cancer therapeutic prevention. Analyses tested the associations between the stated reasons and physician characteristics such as gender, age, country of work and specialty. Of 246 delivered questionnaires, 27 were incomplete and were excluded from analysis. Overall, there was a small variability in response scores, with a tendency for physicians to give moderate importance (score=3) to all 10 statements. However, the top five reasons were: the expected greater preventive effectiveness of aromatase inhibitors (70.3{\%} with score>3), difficulty applying current risk models in clinical practice (69.9{\%}), the lack of clarity on the most appropriate physician for prevention advice (68.4{\%}), the lack of reliable short-term biomarkers of effectiveness (67.5{\%}) and the lack of commercial interest in therapeutic prevention (66.0{\%}). The lack of reliable short-term biomarkers showed a tendency to discriminate between medical oncologists and other breast specialists (OR=2.42, 95{\%} CI, 0.93-6.25). This survey highlights the complexity of prescribing decisions among physicians in this context. Coupled with the known barriers among eligible women, these data may help to identify strategies to increase uptake of breast cancer therapeutic prevention.",
keywords = "Journal Article",
author = "Silvia Noonan and Ambra Pasa and Vincenzo Fontana and Silvia Caviglia and Bernardo Bonanni and Alberto Costa and Smith, {Samuel G} and Fedro Peccatori and Andrea DeCensi",
note = "Copyright {\circledC}2017, American Association for Cancer Research.",
year = "2017",
month = "10",
day = "23",
doi = "10.1158/1940-6207.CAPR-17-0162",
language = "English",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",

}

TY - JOUR

T1 - A survey among breast cancer specialists on the low uptake of therapeutic prevention with tamoxifen or raloxifene

AU - Noonan, Silvia

AU - Pasa, Ambra

AU - Fontana, Vincenzo

AU - Caviglia, Silvia

AU - Bonanni, Bernardo

AU - Costa, Alberto

AU - Smith, Samuel G

AU - Peccatori, Fedro

AU - DeCensi, Andrea

N1 - Copyright ©2017, American Association for Cancer Research.

PY - 2017/10/23

Y1 - 2017/10/23

N2 - With this survey, we aimed to address the reasons why physicians are reluctant to prescribe breast cancer preventive therapy with the selective oestrogens receptor modulators (SERMs) tamoxifen or raloxifene despite a strong evidence of efficacy. A self-administered 5-point Likert questionnaire was given during breast cancer meetings in Europe or sent via email to rank the importance of 10 pre-defined reasons for low uptake of SERMs for breast cancer therapeutic prevention. Analyses tested the associations between the stated reasons and physician characteristics such as gender, age, country of work and specialty. Of 246 delivered questionnaires, 27 were incomplete and were excluded from analysis. Overall, there was a small variability in response scores, with a tendency for physicians to give moderate importance (score=3) to all 10 statements. However, the top five reasons were: the expected greater preventive effectiveness of aromatase inhibitors (70.3% with score>3), difficulty applying current risk models in clinical practice (69.9%), the lack of clarity on the most appropriate physician for prevention advice (68.4%), the lack of reliable short-term biomarkers of effectiveness (67.5%) and the lack of commercial interest in therapeutic prevention (66.0%). The lack of reliable short-term biomarkers showed a tendency to discriminate between medical oncologists and other breast specialists (OR=2.42, 95% CI, 0.93-6.25). This survey highlights the complexity of prescribing decisions among physicians in this context. Coupled with the known barriers among eligible women, these data may help to identify strategies to increase uptake of breast cancer therapeutic prevention.

AB - With this survey, we aimed to address the reasons why physicians are reluctant to prescribe breast cancer preventive therapy with the selective oestrogens receptor modulators (SERMs) tamoxifen or raloxifene despite a strong evidence of efficacy. A self-administered 5-point Likert questionnaire was given during breast cancer meetings in Europe or sent via email to rank the importance of 10 pre-defined reasons for low uptake of SERMs for breast cancer therapeutic prevention. Analyses tested the associations between the stated reasons and physician characteristics such as gender, age, country of work and specialty. Of 246 delivered questionnaires, 27 were incomplete and were excluded from analysis. Overall, there was a small variability in response scores, with a tendency for physicians to give moderate importance (score=3) to all 10 statements. However, the top five reasons were: the expected greater preventive effectiveness of aromatase inhibitors (70.3% with score>3), difficulty applying current risk models in clinical practice (69.9%), the lack of clarity on the most appropriate physician for prevention advice (68.4%), the lack of reliable short-term biomarkers of effectiveness (67.5%) and the lack of commercial interest in therapeutic prevention (66.0%). The lack of reliable short-term biomarkers showed a tendency to discriminate between medical oncologists and other breast specialists (OR=2.42, 95% CI, 0.93-6.25). This survey highlights the complexity of prescribing decisions among physicians in this context. Coupled with the known barriers among eligible women, these data may help to identify strategies to increase uptake of breast cancer therapeutic prevention.

KW - Journal Article

U2 - 10.1158/1940-6207.CAPR-17-0162

DO - 10.1158/1940-6207.CAPR-17-0162

M3 - Article

C2 - 29061559

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

ER -